LCM MRD™ (capillary M-protein)

Highlights:

  • TimepointDx LCM™ MRD was implemented for the detection of M-protein in multiple myeloma patient capillary samples over longitudinal timepoints and compared against mass spectrometry to identify molecular signatures of persistent cancer after treatment.
  • Given that malignant cells persistently "pump" M-protein into the bloodstream, capillary samples were directly correlated with venous samples to confirm biological, spatial, and temporal presence of M-protein in disease-progression and disease-free LCM™ samples.
  • Capillary blood samples were collected via LCM™ at weekly and bi-weekly timepoints for the detection of monoclonal immunoglobulin that is presumably produced by malignant B-cells in multiple myeloma. Additional leukemia samples of both B and T cell origin were incorporated for LCM™ analysis.
  • TimepointDx LCM™ MRD demonstrates potential to identify MRD up to ~165 days faster when compared to single cell VDJ clonality ID.
  • TimepointDx LCM™ identified multiomics signatures correlating to B-cell persistent M-protein production.
  • TimepointDx LCM™ MRD enabled highly sensitive, non-invasive, and dynamic monitoring of M-protein in blood disorders relating to cancer.

See White Paper for Details.

Want the white paper? Contact us below!